MedTrace Logo

Study of Temzolomide and Gleevec in Advanced Melanoma

NCT00667953 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-03-30

Study results available
· View outcomes & findings →

Summary

This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.

Conditions

Interventions

DRUG

Gleevec

Gleevec (600 mg) daily.

DRUG

Temodar

Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.

Sponsors & Collaborators

Principal Investigators

  • Leslie Fecher, MD · Rogel Cancer Center

  • tara mitchell, MD · Abramson CC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2011-03-09
Completion
2011-03-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667953 on ClinicalTrials.gov